Jennifer Doudna is an American biochemist and structural biologist who, with Emmanuelle Charpentier, demonstrated in 2012 that the bacterial CRISPR-Cas9 system could be reduced to two components and directed to cut any chosen DNA sequence by a single engineered guide RNA. The result turned a bacterial immune mechanism into a general-purpose editing tool, and she shared the 2020 Nobel Prize in Chemistry for it. She has since become one of the field's most active voices on governance, particularly on the line between somatic and heritable editing.
Career
Doudna grew up in Hilo, Hawaii, took a degree in biochemistry at Pomona College, and completed a doctorate at Harvard in 1989 with Jack Szostak, working on self-replicating RNA. As a postdoctoral researcher with Thomas Cech in Colorado she solved the crystal structure of a large catalytic RNA domain, one of the first high-resolution views of RNA folding into a defined three-dimensional enzyme.1 Between them, the two projects treated RNA both as an information carrier and as a machine, a combination that set up everything that followed. She joined Yale in 1994 and moved to the University of California, Berkeley, in 2002.
Her laboratory came to CRISPR through structural work on RNA-guided processes rather than through microbiology. Bacterial CRISPR arrays had been described since the late 1980s, and their role in adaptive immunity was established by the mid-2000s; what remained was to show that the system could be reprogrammed. See CRISPR–Cas9 for the full mechanism.
The 2012 result
The paper published with Martin Jinek, Krzysztof Chylinski, Ines Fonfara, Michael Hauer and Charpentier established three things.2 Cas9 is the sole protein required for target cleavage in the type II system. It needs two RNAs, the CRISPR RNA and a trans-activating RNA, which can be fused into a single chimeric guide. And the target is specified by base pairing with that guide, subject to an adjacent short motif in the DNA. Changing twenty nucleotides of the guide changes the target.
Why this was the turning pointProgrammable nucleases already existed. Zinc-finger proteins and TALENs could be targeted, but each new target required designing and building a new protein, which took weeks of work per site. Cas9 moved targeting from protein engineering to ordering an oligonucleotide.
Within months, several groups reported Cas9 editing in human cells, among them teams led by Feng Zhang and by George Church. The tool has since been developed into forms that avoid cutting both DNA strands at all, namely Base editing, Prime editing and Epigenome editing, partly in response to the off-target and large-deletion problems that double-strand breaks create.
Doudna's own later work has centred on the structural biology of Cas enzymes, on anti-CRISPR proteins, on the collateral cleavage activity of Cas12 and Cas13 that underpins CRISPR diagnostics, and on delivery. She has repeatedly identified delivery, rather than the editing chemistry itself, as the field's binding constraint. See Lipid nanoparticles and AAV vectors.
Institutions and companies
Doudna founded the Innovative Genomics Institute in 2014, a joint Berkeley-UCSF centre whose programmes include sickle cell disease, agricultural editing and climate applications, and which ran a high-throughput COVID-19 testing laboratory in 2020. She has co-founded several companies, among them Caribou Biosciences, Intellia Therapeutics, Mammoth Biosciences and Scribe Therapeutics. She was also a founder of Editas Medicine and left it early.
The intellectual-property dispute over CRISPR has unusually large consequences. Berkeley and its partners filed first. The Broad Institute, where Feng Zhang's group demonstrated editing in eukaryotic cells, filed later under an accelerated route and was granted patents covering that use. US interference proceedings have repeatedly favoured the Broad on eukaryotic claims, while European decisions have favoured the Berkeley group; appeals have continued into the mid-2020s, and the American position remains unsettled as of 2026. The scientific credit and the patent position have diverged, which is part of why the case is taught in technology-transfer courses.
Governance
In January 2015 Doudna convened a meeting in Napa, California, that produced a Science commentary calling for a moratorium on clinical use of heritable human genome editing while the science and ethics were worked out.3 Participants explicitly invoked the 1975 Asilomar meeting on recombinant DNA as a template. Critics have questioned the analogy on the grounds that the 1975 participants controlled the entire relevant field and the 2015 participants did not. She has been involved in the international summit process since, and in 2018 condemned the He Jiankui experiment as reckless and premature.
Her position has been consistent and narrower than either extreme. In her view somatic editing is ordinary medicine subject to ordinary safety review, while heritable editing should not proceed clinically until safety, need and societal agreement are all established. She has written about her own unease at having made the tool available, most directly in A Crack in Creation (2017) with Samuel Sternberg.4 She has also persistently criticized the cost structure of approved gene therapies, arguing that a treatment such as Casgevy is of little use to most sickle cell patients, who live in countries where both the price and the transplant infrastructure are out of reach.
Who counts as an inventorPublic credit for CRISPR is contested well beyond Doudna and Charpentier. Francisco Mojica, Rodolphe Barrangou, Philippe Horvath, Virginijus Šikšnys and Feng Zhang all made claims to foundational contributions. The 2020 Nobel recognized two people for a discovery with a long chain of contributors, a familiar structural problem with the prize.
Reception and legacy
Doudna is among the most decorated living biochemists, and CRISPR is now the default laboratory technique for altering a genome in essentially any organism. Clinical translation has been slower than the 2012 excitement implied. As of 2026 a small number of CRISPR-based medicines are approved or in late-stage trials, most of them ex vivo cell therapies or liver-targeted in vivo treatments, and the delivery problem she flagged early remains the reason the list is short.
Her governance work is harder to evaluate. The moratorium she called for has held in the sense that no credible second germline case has been publicly confirmed since 2018. It has held, however, through professional norms, national law and reputational cost rather than through any enforceable international instrument; see Governance of human genome editing. Whether that arrangement survives cheaper editing and stronger commercial incentives around embryo selection is an open question, and she has said the scientific community is not organized to answer it alone.
See also
- CRISPR–Cas9
- Base editing
- Casgevy
- Human germline editing
- He Jiankui affair
- Governance of human genome editing
- George Church
- Off-target effects in genome editing
References
Footnotes
-
paperCate, J. H. et al. "Crystal structure of a group I ribozyme domain: principles of RNA packing." Science, 1996. ↩
-
paperJinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J. A. and Charpentier, E. "A Programmable Dual-RNA-Guided DNA Endonuclease in Adaptive Bacterial Immunity." Science, 2012.↩The demonstration was biochemical, with purified components cutting DNA in a tube; editing inside human cells was reported by other groups months later.
-
paperBaltimore, D. et al. "A prudent path forward for genomic engineering and germline gene modification." Science, 2015.↩A commentary by the meeting's participants urging that clinical germline use be discouraged while research continued; it carried no legal force.
-
bookDoudna, J. A. and Sternberg, S. H. A Crack in Creation: Gene Editing and the Unthinkable Power to Control Evolution. Houghton Mifflin Harcourt, 2017.↩A first-person account by one of the principals, so it records Doudna's own reading of the history rather than an independent one.